Uses of monoclonal antibody 8H9
View Patent ↗This invention provides a composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a suitable carrier. This invention provides a pharmaceutical composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a pharmaceutically acceptable carrier. This invention also provides an antibody other than the monoclonal antibody 8H9 comprising the complementary determining regions of monoclonal antibody 8H9 or a derivative thereof, capable of binding to the same antigen as the monoclonal antibody 8H9. This invention provides a substance capable of competitively inhibiting the binding of monoclonal antibody 8H9. This invention also provides an isolated scFv of monoclonal antibody 8H9 or a derivative thereof. This invention also provides the 8H9 antigen. This invention also provides a method of inhibiting the growth of tumor cells comprising contacting said tumor cells with an appropriate amount of monoclonal antibody 8H9 or a derivative thereof.
1. An antibody produced by the hybridoma 8H9 cell line deposited as ATCC PTA-10926.
2. A composition comprising the antibody of claim 1 .
3. A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.
4. The composition of claim 2 , wherein the antibody is further modified to comprise a detectable label.
5. The composition of claim 3 , wherein the antibody is further modified to comprise a detectable label.
6. The composition of claim 4 , wherein the label is a radiolabel.
7. The composition of claim 5 , wherein the label is a radiolabel.
8. The composition of claim 2 , wherein the antibody is further modified to comprise a cytotoxic agent.
9. The composition of claim 3 , wherein the antibody is further modified to comprise a cytotoxic agent.